keyword
MENU ▼
Read by QxMD icon Read
search

Keynote

keyword
https://www.readbyqxmd.com/read/28636703/transforming-the-national-surgical-quality-improvement-program-to-the-delivery-of-precision-medicine-to-improve-the-value-of-surgical-care-summary-of-the-john-r-clarke-keynote-address-for-the-surgical-outcomes-club-2016-annual-meeting
#1
https://www.readbyqxmd.com/read/28627795/keynote-speaker
#2
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Pediatric Pulmonology
https://www.readbyqxmd.com/read/28621178/interview-with-bernard-siegel
#3
Bernard Siegel
Bernard Siegel is the Founder and full-time Executive Director of the nonprofit Regenerative Medicine Foundation (FL, USA). He is the Founder and the Co-chair of the World Stem Cell Summit series of global conferences and Editor-in-Chief of the World Stem Cell Report. He received his undergraduate and law degrees from the University of Miami (BA, 1972; JD, 1975) and has been a member of the Florida Bar since 1975. As a recognized policy expert relating to stem cell research, regenerative medicine and cloning, Bernard works with the world's leading stem cell researchers and advocates...
June 16, 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/28620848/cost-effectiveness-of-pembrolizumab-vs-standard-of-care-chemotherapy-as-first-line-treatment-for-metastatic-nsclc-that-expresses-high-levels-of-pd-l1-in-the-united-states
#4
Min Huang, Yanyan Lou, James Pellissier, Thomas Burke, Frank Xiaoqing Liu, Ruifeng Xu, Vamsidhar Velcheti
OBJECTIVES: Our objectives were to evaluate the cost effectiveness of pembrolizumab compared with standard-of-care (SoC) platinum-based chemotherapy as first-line treatment in patients with metastatic non-small-cell lung cancer (NSCLC) that expresses high levels of programmed death ligand-1 (PD-L1) [tumour proportion score (TPS) ≥50%], from a US third-party public healthcare payer perspective. METHODS: We conducted a partitioned-survival model with a cycle length of 1 week and a base-case time horizon of 20 years...
June 15, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28616640/-an-open-single-arm-phase%C3%A2-ii-monotherapy-study-of-pembrolizumab-mk-3475-in-locally-advanced-metastatic-renal-cell-carcinoma-mrcc-keynote-427-an-40-16-of-the-auo
#5
https://www.readbyqxmd.com/read/28607520/lung-cancer-keynote-001-combo-improves-melody
#6
Diana Romero
No abstract text is available yet for this article.
July 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28603168/keynote-lecture
#7
(no author information available yet)
No abstract text is available yet for this article.
2017: Experimental Animals
https://www.readbyqxmd.com/read/28601253/lifestyle-determinants-of-health-isn-t-it-all-about-genetics-and-environment
#8
Margaret Grey
PURPOSE: Drawn from one of the keynote addresses at the State of the Science Conference held by the Council for the Advancement of Nursing Science (CANS), the purpose of this paper is to review the evidence from clinical trials about the importance of lifestyle behaviors in human health. METHODS: Evidence from trials on the impact of lifestyle interventions on outcomes in diabetes and prediabetes are presented. RESULTS: These findings suggest that lifestyle behaviors are important to diabetes prevention and outcomes in youth and adults...
May 10, 2017: Nursing Outlook
https://www.readbyqxmd.com/read/28596257/developments-in-molecular-testing-and-biosimilars
#9
Katy Winckworth-Prejsnar, Elizabeth A Nardi, Lisa Korin Lentz, Jeffrey A Crawford, C Lyn Fitzgerald, Robert W Carlson
Molecular testing and biosimilars offer the potential for increased access to targeted treatment options and reduction in healthcare costs, but come with significant challenges in ensuring patient access to innovation in cancer care while maintaining safe, effective, ethical, and affordable treatment options. As providers, payers, patients, and the larger healthcare systems become inundated with a wide variety of molecular diagnostics and an increased number of biosimilars coming to market, it will be important to understand regulatory guidance and policy implications relating to the appropriateness of molecular testing and the clinical use of biosimilars in cancer care...
June 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28594307/5th-congress-of-wuwhs-abstract-book-florence-italy-september-25-29-2016
#10
(no author information available yet)
The abstract book contains the abstracts of keynote lectures, focus sessions, symposia, workshops, AIUC annual meeting, AISLEC annual meeting, EPUAP annual meeting, ETRS special session, sponsor symposia, oral presentations, poster presentations and the subject index.
June 1, 2017: Journal of Wound Care
https://www.readbyqxmd.com/read/28585617/-immunotherapy-for-lung-cancer
#11
Gyula Ostoros
Similarly to other malignancies, immune checkpoint inhibitor therapy is a revolutionary, effective new treatment possibility for lung cancer. In lung cancer carcinogenesis is related mainly to tobacco smoking with high somatic mutation rate and immunogenicity. The PD-1 inhibitor nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab is a labelled indication in second line setting in advanced nonsmall cell lung cancer (NSCLC). Avelumab and durvalumab have promising activity as well. Based on the data of KEYNOTE 024 trial, pembrolizumab is approved in first line setting for cases with ≥50% PD-L1 expression...
June 6, 2017: Magyar Onkologia
https://www.readbyqxmd.com/read/28576650/steroid-metabolism-in-the-brain-from-bird-watching-to-molecular-biology-a-personal-journey
#12
REVIEW
Jacques Balthazart
Since Arnold Adolph Berthold established in 1849 the critical role of the testes in the activation of male sexual behavior, intensive research has identified many sophisticated neurochemical and molecular mechanisms mediating this action. Studies in Japanese quail demonstrated the critical role of testosterone action and of testosterone aromatization in the sexually dimorphic medial preoptic nucleus in the activation of male copulatory behavior. The development of an immunohistochemical visualization of brain aromatase in quail then allowed further refinement in the localization of the sites of neuroestrogens production...
June 4, 2017: Hormones and Behavior
https://www.readbyqxmd.com/read/28571578/immunotherapy-in-head-and-neck-cancer-aiming-at-extreme-precision
#13
Petr Szturz, Jan B Vermorken
BACKGROUND: Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic treatment often forms an integral part of their management. Immunotherapy is based on functional restoration of the host immune system, helping to counteract various tumour evasion strategies. Broadly, immunotherapeutic approaches encompass tumour-specific antibodies, cancer vaccines, cytokines, adoptive T-cell transfer, and immune-modulating agents...
June 2, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28551359/previous-radiotherapy-and-the-clinical-activity-and-toxicity-of-pembrolizumab-in-the-treatment-of-non-small-cell-lung-cancer-a-secondary-analysis-of-the-keynote-001-phase-1-trial
#14
Narek Shaverdian, Aaron E Lisberg, Krikor Bornazyan, Darlene Veruttipong, Jonathan W Goldman, Silvia C Formenti, Edward B Garon, Percy Lee
BACKGROUND: Preclinical studies have found radiotherapy enhances antitumour immune responses. We aimed to assess disease control and pulmonary toxicity in patients who previously received radiotherapy for non-small-cell lung cancer (NSCLC) before receiving pembrolizumab. METHODS: We assessed patients with advanced NSCLC treated on the phase 1 KEYNOTE-001 trial at a single institution (University of California, Los Angeles, CA, USA). Patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 1 or less, had adequate organ function, and no history of pneumonitis...
May 24, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28550612/keynote-symposium
#15
(no author information available yet)
No abstract text is available yet for this article.
May 26, 2017: In Vitro Cellular & Developmental Biology. Animal
https://www.readbyqxmd.com/read/28533473/u-s-food-and-drug-administration-approval-summary-pembrolizumab-for-the-treatment-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-with-disease-progression-on-or-after-platinum-containing-chemotherapy
#16
Erin Larkins, Gideon M Blumenthal, Weishi Yuan, Kun He, Rajeshwari Sridhara, Sriram Subramaniam, Hong Zhao, Chao Liu, Jingyu Yu, Kirsten B Goldberg, Amy E McKee, Patricia Keegan, Richard Pazdur
On August 5, 2016, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth, NJ) for treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. Approval was based on the objective response rate (ORR) and duration of response (DoR) in a cohort of patients in a nonrandomized multi-cohort trial (KEYNOTE-012) that included 174 patients with recurrent or metastatic HNSCC who had disease progression on or after platinum-containing chemotherapy...
May 22, 2017: Oncologist
https://www.readbyqxmd.com/read/28515247/keynote-address-when-breath-becomes-air-as-physician-becomes-patient
#17
Lucy Kalanithi, Heather Wakelee, Robert W Carlson
As part of the NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care, Lucy Kalanithi, MD, wife of now-deceased best-selling author Paul Kalanithi (When Breath Becomes Air), and Heather Wakelee, MD, Paul's oncologist, discussed-for the first time together in a public forum-Paul's experience of going from a neurosurgery resident to a patient with cancer with a terminal diagnosis. Robert Carlson, MD, moderated the discussion.
May 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28493171/immunotherapy-in-urothelial-cancer-recent-results-and-future-perspectives
#18
REVIEW
Matthew S Farina, Kevin T Lundgren, Joaquim Bellmunt
Cytotoxic chemotherapy has been the only systemic treatment of locally advanced and metastatic urothelial carcinoma for decades. Long-term survival remains stagnant around 12-14 months for patients with advanced disease who have progressed on or recurred after receiving first-line platinum-based chemotherapy. Improving clinical outcomes for patients with urothelial carcinoma in all disease settings requires the development of novel treatments, especially for patients who failed on first-line chemotherapy. Since the discovery of intravesical Bacillus-Calmette Guerin (BCG) in the 1970s for non-muscle invasive disease, there have not been any major breakthrough drugs that exploit the immune-sensitivity of bladder cancer until recently...
May 11, 2017: Drugs
https://www.readbyqxmd.com/read/28490569/safety-tolerability-of-pembrolizumab-in-patients-with-relapsed-refractory-primary-mediastinal-large-b-cell-lymphoma
#19
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Yayan Zhang, Sabine Chlosta, Margaret A Shipp, Philippe Armand
Treatment options for relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited and prognosis is generally poor (overall response rate [ORR] 0-25%; 2-year overall survival 15%). PMBCL frequently involves PD-1 ligand overexpression, potentially making PMBCL particularly susceptible to PD-1 blockade. We evaluated safety and antitumor activity of pembrolizumab, an anti-PD-1 antibody, in rrPMBCL as part of the KEYNOTE-013 multicohort Phase 1b trial. At time of data cutoff, 18 patients (median age 30; median 3 prior lines of therapy) had been enrolled and treated, of whom 17 were included in the efficacy analyses...
May 10, 2017: Blood
https://www.readbyqxmd.com/read/28489510/safety-and-antitumor-activity-of-pembrolizumab-in-advanced-programmed-death-ligand-1-positive-endometrial-cancer-results-from-the-keynote-028-study
#20
Patrick A Ott, Yung-Jue Bang, Dominique Berton-Rigaud, Elena Elez, Michael J Pishvaian, Hope S Rugo, Igor Puzanov, Janice M Mehnert, Kyaw L Aung, Juanita Lopez, Marion Carrigan, Sanatan Saraf, Mei Chen, Jean-Charles Soria
Purpose The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti-programmed death 1 monoclonal antibody, in patients with programmed death ligand 1 (PD-L1) -positive advanced solid tumors. The results from the advanced endometrial cancer cohort are reported. Patients and Methods Female patients with locally advanced or metastatic PD-L1-positive endometrial cancer who had experienced progression after standard therapy were eligible. Patients received pembrolizumab 10 mg/kg every 2 weeks for up to 24 months or until progression or unacceptable toxicity...
May 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
56519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"